PEPG - PepGen Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$4.00
DETAILS
HIGH:
$4.00
LOW:
$4.00
MEDIAN:
$4.00
CONSENSUS:
$4.00
UPSIDE:
27.39%
About PepGen Inc. (https://www.pepgen.com)
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| James G. McArthur | President, Chief Executive Officer, Treasurer, Secretary & Director | 1962 | $1,057,616 USD |
| Noel Donnelly | Chief Financial Officer | 1970 | $742,595 USD |
| Joseph D. Vittiglio | Chief Business & Legal Officer and Secretary | 1972 | $391,638 USD |
| Paul D. Streck | Executive Vice President and Head of Research & Development | 1964 | $332,733 USD |
| Emiko Bryant | Senior Vice President of HR & Administration | – | – |
| Gregory Song | Executive Director & Head of Biometrics | – | – |
| Hayley Parker | Senior Vice President of Global Regulatory Affairs & Quality | – | – |
| Kasra Kasraian | Chief Technology Officer | 1967 | – |
| Melissa Michaels | Executive Director & Head of Regulatory Affairs CMC | – | – |
| Pallavi Lonkar | Vice President & Head of Preclinical | – | – |